华东医药：2022年半年度报告（英文版）.PDF

1、Semi-Annual Report 2022 of Huadong Medicine Co.,Ltd.1 Huadong Medicine Co.,Ltd.Semi-Annual Report 2022 August 2022 Semi-Annual Report 2022 of Huadong Medicine Co.,Ltd.2 Section I.Important Declaration,Contents and Definitions The Board of Directors,Board of Supervisors,directors,supervisors and seni

2、or management of Huadong Medicine Co.,Ltd.(hereinafter referred to as the“Company”)hereby guarantee that the information presented in this half year report is authentic,accurate and complete and free of any false records,misleading statements or material omissions,and shall undertake individual and

3、joint legal liabilities.Lv Liang,the Companys legal representative and the officer in charge of accounting,and Qiu Renbo,head of accounting department(accounting supervisor)hereby declare and guarantee that the financial statements in this half year report are authentic,accurate and complete.All dir

4、ectors have attended the Board of Directors meeting to review this half year report.The future plans,development strategies and other forward-looking statements in this half year report shall not be considered as substantial commitment of the Company to investor.Investors and related parties should

5、maintain sufficient risk awareness,and should understand the difference between plans,forecasts and promises.The risks the Company faces in operation including industry policy and market operation risk,new drug R&D risk,exchange rate fluctuation risk and goodwill impairment risk,etc.For details,refe

6、r to“X.Risks and Countermeasures”in“Section III.Discussion and Analysis of the Management”.We thank all investors for paying attention to the Companys operations,and we hope that you can be aware of investment risks.The company does not plan to distribute cash dividends,no bonus share will be issued